Latest content from Pharmetheus.
Effective feedback and feedforward of information across and within compounds can promote an environment of “joined-up thinking” within organizations. This is an important element of model-informed drug development (MIDD) as we obtain insights on a compound’s properties by efficiently leveraging accumulated data. These insights can be used to frame the most impactful compound-related risks and shape contingency plans that enable these risks to be managed/mitigated appropriately. MIDD can greatly aid the ability of decision makers to arrive at strategy and/or study design achieving a favorable outcome. Meet Peter Milligan and Richard Anziano, sharing their experiences from implementing this type of collaborative quantitative framework within a top pharmaceutical company and how they currently support clients with MIDD-related questions.